Baltpharma has received construction approval for a pharmaceutical plant at the Novoorlovskaya site within the St. Petersburg special economic zone, with project investments exceeding 2.5 billion rubles, the St. Petersburg television channel reported. The production launch is planned for the second quarter of 2026.
OOO Baltpharma was registered in St. Petersburg in 2016. The company’s primary business is manufacture of pharmaceutical substances. Just over a year ago, AO R-Pharm became the sole owner of the company. As reported at the time, R-Pharm was implementing the project at Novoorlovskaya, where it had acquired Baltpharma along with a constructed building that had been completed, under an offset contract. According to the contract, the plant will produce 31 types of pharmaceutical drugs in a full cycle. The city, in turn, will purchase this output for seven years without competitive tender procedures to supply designated beneficiary categories, which also guarantees utilization of the production capacity.
“The enterprise launch was scheduled for 2025, and for now, we are optimistic about these timelines,” St. Petersburg Vice-Governor Kirill Polyakov said last November.
